B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.

K, Yonesaka; K, Haratani; S, Takamura; H, Sakai; R, Kato; N, Takegawa; T, Takahama; K, Tanaka; H, Hayashi; M, Takeda; S, Kato; O, Maenishi; K, Sakai; Y, Chiba; T, Okabe; K, Kudo; Y, Hasegawa; H, Kaneda; M, Yamato; K, Hirotani; M, Miyazawa; K, Nishio; K, Nakagawa

doi:10.1158/1078-0432.ccr-17-2852

Public

B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.

Shared by NobleBlocks on Mar 12, 2018 • 12:00 AM UTC

Authors:

Yonesaka K

Haratani K

Takamura S

Abstract

<b>Purpose:</b> Anti-programmed-death-1 (PD-1) immunotherapy improves survival in non-small cell lung cancer (NSCLC), but some cases are refractory to treatment, thereby requiring alternative strategies. B7-H3, an immune-checkpoint molecule, is expressed in various malignancies. To our knowledge, th...

Discussions